Open Payments

Newyork-Presbyterian/Queens

Type
Teaching hospital
Where
FLUSHING, NY
Medicare CCN
330055
Received
$549,202 in 44 records, 2024 ($196,843 general, $352,358 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment18$196,843
2024Research payment26$352,358

By company

CompanyRecordsAmountYears
Gilead Sciences, Inc.5$243,8462024
Merck Sharp & Dohme LLC1$80,1532024
Novartis Pharmaceuticals Corporation2$79,6362024
Chiesi USA, Inc.12$48,5872024
Volta Medical Inc2$29,4372024
Stryker Corporation4$20,1782024
Boston Scientific Corporation5$19,0522024
ENDOTRONIX, INC.1$8,8502024
AstraZeneca Pharmaceuticals LP2$5,0002024
Linvatec Corporation1$3,2732024
BIOTRONIK INC.2$2,7132024
PFIZER INC.1$2,5002024
Abbott Laboratories1$2,5002024
Boehringer Ingelheim Pharmaceuticals, Inc.1$2,5002024
KLS-Martin L.P.3$8802024
Barco, Inc.1$932024

By nature of payment

NatureRecordsAmount
Research payment26$352,358
Grant2$157,204
Debt forgiveness6$17,623
Space rental or facility fees (teaching hospital only)5$12,500
Long term medical supply or device loan3$6,922
Compensation for services other than consulting, including serving as faculty or as a speaker at a v1$2,500
Food and Beverage1$93

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Stryker Corporation$16,314Debt forgivenessCash or cash equivalent2024
2024-12-31ENDOTRONIX, INC.$8,850Research paymentCash or cash equivalentCORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILUREPROACTIVE-HF2024
2024-12-31Stryker Corporation$3,458Long term medical supply or device loanIn-kind items and servicesPRIME SERIES Device, PATIENT HANDLING - PH2024
2024-12-31Stryker Corporation$215Debt forgivenessCash or cash equivalent2024
2024-12-31Stryker Corporation$190Long term medical supply or device loanIn-kind items and servicesStryker F1 Device, INSTRUMENTS2024
2024-12-24Barco, Inc.$93Food and BeverageCash or cash equivalent2024
2024-12-06Chiesi USA, Inc.$3,983Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-11-25Gilead Sciences, Inc.$154,704GrantCash or cash equivalent2024
2024-11-13Chiesi USA, Inc.$6,116Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-11-13Chiesi USA, Inc.$5,570Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-11-01Chiesi USA, Inc.$4,200Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-10-23Chiesi USA, Inc.$2,599Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-10-17Volta Medical Inc$16,450Research paymentCash or cash equivalentVX1 Device, CardiovascularCompanion AI2024
2024-09-26Boston Scientific Corporation$1,921Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2024
2024-09-18Chiesi USA, Inc.$1,384Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-08-31BIOTRONIK INC.$213Debt forgivenessCash or cash equivalentSelectra Device, Cardiology/Vascular Diseases2024
2024-08-27Boston Scientific Corporation$10,191Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2024
2024-08-14Chiesi USA, Inc.$1,384Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-07-18Gilead Sciences, Inc.$14,467Research paymentCash or cash equivalentSunlenca Drug, HIVA Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt2024
2024-06-26Chiesi USA, Inc.$2,599Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-06-25Boston Scientific Corporation$439Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2024
2024-06-05Chiesi USA, Inc.$3,435Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-06-04KLS-Martin L.P.$528Debt forgivenessCash or cash equivalentLEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 1.5 MM TISSUE COLLAR, 1.5 X 8 MM THD, TTL=13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis2024
2024-06-04KLS-Martin L.P.$176Debt forgivenessCash or cash equivalentLEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 1.5 MM TISSUE COLLAR, 2.0 X 10 MM THD, TTL=15 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis2024
2024-06-04KLS-Martin L.P.$176Debt forgivenessCash or cash equivalentLEVEL ONE ORTHOANCHOR, SCREW, MAXDRIVE, DRILL FREE, 2.0 MM TISSUE COLLAR, 2.0 X 8 MM THD, TTL=13 MM, TI-6AL-4V, QTY: 001 EA Device, Osteosynthesis2024
2024-05-15Chiesi USA, Inc.$8,715Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-05-10Chiesi USA, Inc.$1,352Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-05-09Volta Medical Inc$12,987Research paymentCash or cash equivalentVX1 Device, CardiovascularTailored-AF2024
2024-03-22Boston Scientific Corporation$2,500GrantIn-kind items and servicesWATCHMAN Device, WATCHMAN Pro_IC2024
2024-03-01PFIZER INC.$2,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2024
2024-02-28Novartis Pharmaceuticals Corporation$10,060Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA randomized, multicenter, open-label trial comparing the effectiveness of an "inclisiran first" implementation strategy2024
2024-02-22Novartis Pharmaceuticals Corporation$69,576Research paymentCash or cash equivalentLEQVIO Drug, Cardiology/Vascular DiseasesA Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo2024
2024-02-19Linvatec Corporation$3,273Long term medical supply or device loanIn-kind items and servicesMENISCAL REPAIR DEVICES Device, ORTHOPEDIC SURGERY2024
2024-02-13Gilead Sciences, Inc.$52,960Research paymentCash or cash equivalentVeklury Drug, COVID-19Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir2024
2024-02-13Gilead Sciences, Inc.$15,040Research paymentCash or cash equivalentVeklury Drug, COVID-19Incidence of Acute Kidney Disease in COVID-19 Patients Receiving Remdesivir2024
2024-02-08Gilead Sciences, Inc.$6,675Research paymentCash or cash equivalentSunlenca Drug, HIVAcceptability of Long-Acting Injectable Lenacapavir Among Heavily Treatment Experienced Individuals with HIV within the 2024
2024-02-07Chiesi USA, Inc.$7,250Research paymentCash or cash equivalentA Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Du2024
2024-01-31Abbott Laboratories$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentXIENCE ALPINE Device, Vascular2024
2024-01-31Boehringer Ingelheim Pharmaceuticals, Inc.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-22BIOTRONIK INC.$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-19AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-01-17AstraZeneca Pharmaceuticals LP$2,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentFARXIGA Drug, Cardiovascular and Metabolism2024
2024-01-16Boston Scientific Corporation$4,000Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_CRMLUX-DX TRENDS2024
2024-01-15Merck Sharp & Dohme LLC$80,153Research paymentCash or cash equivalentZERBAXA Drug, INFECTIOUS DISEASESTUDY NAME#Impact of an Acute-Care Antimicrobial Stewardship Programs Interventional Collaboration on Antimicrobial Use 2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

In New York; placed by its state only.

MeasureState
New York
Population B0100319,852,366
Population, 2020 census P120,201,249
Median age B0100239.8
Under 18 B0100120.5%
65 and over B0100117.9%
Households B110017,722,646
Foreign born B0500222.8%
Median household income B19013$85,974
Median family income B19113$106,873
Per capita income B19301$50,712
Poverty rate B1700114.0%
Unemployment rate B230256.4%
Civilian labor force B2302510,171,766
Mean commute (minutes) B0801332.6
Bachelor's degree or higher B1500340.2%
Housing units B250018,585,241
Owner-occupied B2500354.3%
Renters B2500345.7%
Median home value B25077$423,800
Median gross rent B25064$1,621
White, not Hispanic B0300252.8%
Black B0300213.4%
Hispanic or Latino B0300219.8%
Asian B030029.0%
American Indian and Alaska Native B030020.2%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New York.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.